Biotech | March 12, 2022
BioPharma’s Herceptin biosimilar Phase 3 results positive
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
The study looked at 1,364 children in Arizona, Florida, Texas, and Utah who submitted weekly nasal swabs and surveys from July 2021 through February 2022, regardless of whether they had symptoms
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
Data from this study will support a submission to expand the use of atogepant to include preventive treatment of chronic migraine in the United States and additional submissions globally
Experts will speak about primary tumours of the nervous system and also the tumours of other body parts which get metastasized to the nervous system
Moderna's Omicron-specific bivalent booster candidate combines its Omicron-specific booster candidate with its Covid-19 vaccine
Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
Over the last 35 years, Dr. Moopen – Founder Chairman and Managing Director of Aster DM Healthcare has played a phenomenal role in strengthening the healthcare delivery system in GCC
Partners with GITAM University to train 27 employees through a 10-day HR module and make them future-ready
SAATH is a ‘One AXA’ public health initiative between AXA France Vie, AXA GO Business Operations, and AXA XL
Subscribe To Our Newsletter & Stay Updated
